U.S. Food and Drug Administration Approves OPDIVO® in Combination with CABOMETYX® as First-line Treatment for Patients with Advanced Renal Cell Carcinoma Biotech Investing
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021 Biotech Investing
Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19 Biotech Investing
HempFusion Announces Large-Scale Distribution Agreement with Fullscript.com to Launch Doctor Practitioner Sales Channel Biotech Investing
Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. Biotech Investing
BioHarvest Sciences Inc. Shareholder Update - Live Event January 21, 2021 at 2:00 PM Eastern Standard Time Biotech Investing
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer Biotech Investing
